

2. Murphy LA, White IR. Contact dermatitis from geraniol in washing-up liquid. *Contact Dermatitis* 2003; **49**: 52.
3. Tamagawa-Mineoka R, *et al*. Allergic contact cheilitis due to geraniol in food. *Contact Dermatitis* 2007; **56**: 242–3.

Preparations

Proprietary Preparations (details are given in Part 3)
USA: Cholestin.
Multi-ingredient: **Canad.:** Natrapel; **Fr.:** Biolaur; Moustidose.

Geranium Oil

Aetheroleum Pelargonii; Geranii Etheroleum; Geranio, aceite esencial de; Geraniová silice; Oleum Geranii; Pelargonium Oil; Rose Geranium Oil.
Гераниевое Масло
Profile
Geranium oil is a volatile oil obtained by distillation from the aerial parts of various species and hybrid forms of *Pelargonium* (Geraniaceae). It contains geraniol (p.2310). It is used to perfume various preparations and has been included in insect repellent preparations. It is also used in aromatherapy.

Adverse effects. Allergic reactions have been reported¹ with herbal preparations containing extracts of *Pelargonium sidoides* and *P. reniforme* used for respiratory-tract infections.
1. de Boer HJ, *et al*. Allergic reactions to medicines derived from *Pelargonium* species. *Drug Safety* 2007; **30**: 677–80.

Postherpetic neuralgia. A study¹ involving 30 patients has indicated that topically applied geranium oil is of benefit in the management of the pain of postherpetic neuralgia. Pain relief was obtained within a few minutes but further study is required to determine the duration of effect beyond 1 hour. Adverse effects were considered to be minor and included burning in the eye, skin rash, and lightheadedness.
1. Greenway FL, *et al*. Temporary relief of postherpetic neuralgia pain with topical geranium oil. *Am J Med* 2003; **115**: 586–7.

Preparations

Proprietary Preparations (details are given in Part 3)
Braz.: Kaloba; Umckant; **Ger.:** Umckaloabo; **Ital.:** Entom Nature; **Mex.:** Umckaloabo; **Rus.:** Umckalor (Умкчалор); **UK:** Kaloba; **Venez.:** Kaloba.
Multi-ingredient: **Fr.:** Acaridif; Sedermyl Actifroid; **Ger.:** Rosatum Heilsalbe; **Ital.:** Air Citronella; Dentosan Azione Intensiva; Dentosan Mese; Mistick Verde; Otosan Natural Ear Drops; **NZ:** Mr Nits; **UK:** Medicated Extract of Rosemary; Nostroline; Teenstick.

Germanium

Germanio.
Ge = 72.64.
CAS — 7440-56-4.

Profile

Germanium compounds have been used in dietary supplements promoted for conditions including cancer, chronic fatigue syndrome, and immunodeficiency disorders. However, germanium compounds can produce severe renal damage and their use should be discouraged.
Germanium has also been used in dental alloys and has various industrial uses.
Effects on the kidneys. In the UK the DOH has recommended that germanium should not be taken as a dietary supplement because of a significant incidence of renal toxicity. There have been a number of reports of severe renal damage, including fatalities, resulting from germanium ingestion.

References.
1. Okada K, *et al*. Renal failure caused by long-term use of a germanium preparation as an elixir. *Clin Nephrol* 1989; **31**: 219–24.
2. van der Spoel JJ, *et al*. Dangers of dietary germanium supplements. *Lancet* 1990; **336**: 117. Correction. *ibid*. 1991; **337**: 864.
3. Schauss AG. Nephrotoxicity in humans by the ultratrace element germanium. *Ren Fail* 1991; **13**: 1–4.
4. Hess B, *et al*. Tubulointerstitial nephropathy persisting 20 months after discontinuation of chronic intake of germanium lactate citrate. *Am J Kidney Dis* 1993; **21**: 548–52.
5. Tao SH, Bolger PM. Hazard assessment of germanium supplements. *Regul Toxicol Pharmacol* 1997; **25**: 211–19.
6. Swennen B, *et al*. Epidemiological survey of workers exposed to inorganic germanium compounds. *Occup Environ Med* 2000; **57**: 242–8.

Ginkgo Biloba

Árbol de los cuarenta escudos; EGB-761; Fossil Tree; GBE-761; Ginkgo, feuille de (ginkgo leaf); Ginkgo folium (ginkgo leaf); Ginkgoblád (ginkgo leaf); Ginkmedžij lapai (ginkgo leaf); Jinanový list (ginkgo leaf); Kew Tree; Maidenhair Tree; Neidondhiuspunlehti (ginkgo leaf); Páfrányfenyőlevél (ginkgo leaf); Salisburia adiantifolia.
Гинкго Билоба
ATC — N06DX02.
ATC Vet — QN06DX02.
Pharmacopoeias. In *Chin.*, *Eur.* (see p.vii), and *US. Eur.* (see p.vii) also includes Ginkgo Dry Extract, Refined and Quantified. *US* includes a powdered extract.
Ph. Eur. 6.2 (Ginkgo Leaf). The whole or fragmented dried leaf

of *Ginkgo biloba* containing not less than 0.5% of flavonoids, calculated as flavone glycosides with reference to the dried drug. The leaf is greyish or yellowish-green or yellowish-brown.
USP 31 (Ginkgo). The dried leaf of *Ginkgo biloba* (Ginkgoaceae) containing not less than 0.5% of flavonoids, calculated as flavonol glycosides, with a mean molecular mass of 756.7, and not less than 0.1% of terpene lactones, both on the dried basis. The leaf is khaki green to greenish-brown. Protect from light and moisture.

Adverse Effects

Adverse effects include headaches, dizziness, palpitations, gastrointestinal disturbances, bleeding disorders, and skin hypersensitivity reactions.
Poisoning. Reports^{1,2} of convulsions induced by ingestion of large amounts of ginkgo seeds. Convulsions were thought to be due to the presence of 4-metoxypyridoxine, a competitive antagonist of pyridoxine; giving suitable quantities of a vitamin-B₆ source may be of benefit in preventing such convulsions.²

1. Miwa H, *et al*. Generalized convulsions after consuming a large amount of ginkgo nuts. *Epilepsia* 2001; **42**: 280–1.
2. Kajiyama Y, *et al*. Ginkgo seed poisoning. *Pediatrics* 2002; **109**: 325–7.

Interactions

It has been suggested that ginkgo biloba should be used with caution in patients receiving anticoagulants or drugs that affect platelet aggregation. For reference to a possible interaction with warfarin, see p.1431.

Uses and Administration

An extract from the leaves of *Ginkgo biloba* has been used in cerebrovascular and peripheral vascular disorders. It is also being investigated in Alzheimer's disease, multi-infarct dementia, and in tinnitus. *Ginkgo biloba* is a source of ginkgolides (below).
Homoeopathy. Ginkgo biloba has been used in homoeopathic medicines under the following names: Ginkgo.

Cerebrovascular disorders. A systematic review¹ of 10 randomised or quasi-randomised studies concluded that the routine use of ginkgo biloba extracts to promote recovery after ischaemic stroke was not supported by any convincing evidence, and that larger better quality studies were required.

1. Zeng X, *et al*. Ginkgo biloba for acute ischaemic stroke. Available in the Cochrane Database of Systematic Reviews; Issue 4. Chichester: John Wiley; 2005 (accessed 23/05/06).

Dementia. Ginkgo biloba extracts have been tried in the treatment of dementia including Alzheimer's disease (p.362). Meta-analyses^{1–3} have found the extracts to be more effective than placebo in some cases but results are inconsistent and unconvincing³ and the authors of all analyses commented that further investigation is needed to establish any clinical value. A subsequent study found no evidence of benefit.⁴ Another study assessing whether ginkgo biloba can prevent cognitive decline in very elderly people with normal memory function found positive effects only after adjustment for noncompliance.⁵ In this study⁵ a greater number of cases of stroke or transient ischaemic attacks was noted in those given ginkgo biloba but further study is required to confirm any link to use of ginkgo.

1. Oken BS, *et al*. The efficacy of ginkgo biloba on cognitive function in Alzheimer disease. *Arch Neurol* 1998; **55**: 1409–15.
2. Ernst E, Pittler MH. Ginkgo biloba for dementia: a systematic review of double-blind, placebo-controlled trials. *Clin Drug Invest* 1999; **17**: 301–8.
3. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Available in The Cochrane Database of Systematic Reviews; Issue 2. Chichester: John Wiley; 2007 (accessed 02/05/08).
4. McCarney R, *et al*. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. *Int J Geriatr Psychiatry* 2008. Available at: doi: 10.1002/gps.2055
5. Dodge HH, *et al*. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. *Neurology* 2008; **70**: 1809–17.

Peripheral vascular disorders. Ginkgo biloba extracts have been tried in the treatment of peripheral vascular disorders (p.1178). A meta-analysis¹ found the extracts to be more effective than placebo in the symptomatic treatment of intermittent claudication, although the authors considered the size of the effect to be modest and of uncertain clinical relevance.

1. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. *Am J Med* 2000; **108**: 276–81.

Tinnitus. Ginkgo biloba extracts have been tried in the treatment of tinnitus (p.1866). A systematic review¹ of 5 randomised controlled studies cautiously concluded that these results were favourable, although a later systematic review² failed to show benefit.

1. Ernst E, Stevinson C. Ginkgo biloba for tinnitus: a review. *Clin Otolaryngol* 1999; **24**: 164–7.
2. Hilton M, Stuart E. Ginkgo biloba for tinnitus. Available in The Cochrane Database of Systematic Reviews; Issue 2. Chichester: John Wiley; 2004 (accessed 23/05/06).

Preparations

USP 31: Ginkgo Capsules; Ginkgo Tablets.


Proprietary Preparations (details are given in Part 3)
Arg.: Clarviv; Herbaccion Cerebral; Kalter; Tanakan; **Austral.:** Proginogin; Tavonin; **Austria:** Cerebokan; Ceremin; Gingoheal; Gingol; Tebofortan; Tebonin; **Belg.:** Memfit; Tanakan; Tavonin; **Braz.:** Binkof; Bioflavin; Cli-

bium; Dinaton; Equitam; Gibilon; Ginkbiloba; Gincobem; Gincolin; Ginkoba; Ginkobil; Ginkofarma; Ginkogreen; Ginkolab; Ginkomed; Ginkoplus; Gyncobem; Kiadon; Kirsan; Mensana; Oxian; Tanakan; Tebonin; **Chile:** Kiadon; Memokit; Ment Vital; Nolatari; Rokan; Tebokan; **Cz.:** Gingio; Gium; Tanakan; Tebokan; **Fr.:** Ginkogin; Tanakan; Tramisal; **Ger.:** Aliz; Dugogin; Gincurant; Ginkloba; Gingium; Ginkobeta; Ginkopret; Ginkobil; Ginkodiat; Ginkokant; Ginkopur; Isoginkin; Kaverin; Rokan; Tebonin; **Gr.:** Tanacan; Tebokan; **Hong Kong:** Ebamin; Ginkolin; **Hung.:** Bilobil; Gingium; Ginkgold; Tanakan; Tebofortan; Tebonin; **Indon.:** Brenax; Ginkgan; Ginkgoforce; Ginkona; Lanaginkola; **Ital.:** Ginkoba; Novel Ginkgo; **Malaysia:** Appeton Memocap; Globa; Gincare; Ginkoceri; Tanakan; **Mex.:** Biogink; Kolob; Nemori; Tanakan; Tebonin; Vasodil; **Neth.:** Tavonin; **Philipp.:** Ginkoc; Tebokan; **Pol.:** Bilobil; Geriacaps; Ginkgomax; Ginkofar; Herbabiloba; Memoplant; Tanakan; **Port.:** Abolibe; Biloban; Gincoben; Ginkofal; Vasacife; **Rus.:** Bilobil (Билобил); Ginos (Гинос); Memoplant (Мемоплант); Tanakan (Танакан); **Singapore:** Gincare; Ginxin-F; Ginkapran; Ginkosen; Gitako; Neuroxin; Tanakan; Tebonin; **Spain:** Fitokei Ginkgo; Normocin; Tanakene; **Switz.:** Demonatur Ginkgo; Geniaforce; Gingosol; Oxavel; Symfona; Tanakene; Tebofortin; Tebokan; Valverde Vitalite dragees; **Thai.:** Tanakan; **Turk.:** Ginkobil; Tanakan; **UK:** Ginkovital; **USA:** BioGinkgo; **Venez.:** Kiadon; Neukob; Tanakan; Tebokan; Varginko.

Multi-ingredient: **Arg.:** Centellase de Centella Queen; Flebitol; Garcinol Max; GB 100; Ginkgo Biloba Forte; Ginkgo Biloba Memo Diates; Ginkgo Forte; Herbaccion Celfin; Herbaccion Memory; Neuroton; **AST.:** Bilberry Plus Eye Healthy; Biogan Vision-Eze; Biogan Zellulene with Escin; Clem-ents Tonic; Extralife Extra-Brite; Extralife Eye-Care; Extralife Leg-Care; Eye Health Herbal Plus Formula 4; For Peripheral Circulation Herbal Plus Formula 5; Gingo A; Ginkgo Biloba Plus; Ginkgo Complex; Ginkgo Plus Herbal Plus Formula 10; Herbal Arthritis Formula; Herbal Capillary Care; Lifechange Circulation Aid; Lifechange Multi Plus Antioxidant; Lifestem Herbal Formula 6 For Peripheral Circulation; Lifestem Herbal Plus Formula 11; Ginkgo; Lifestem Herbal Plus Formula 5 Eye Relief; Prophthal; **Vig. Braz.:** Composto Anticelulítico; Derm'active Solaire; Traumed; **Canad.:** Ginkoba; **Chile:** Celtech Gold; Gincosan; Gingo-Ther; Mentania; Sebiom AKN; **Cz.:** Gincosan; Ginkor Fort; **Fr.:** Ginkor; Ginkor Fort; Photoderm Flush; Sebiom AKN; **Ger.:** Perivar; Veno-Tebonin; **Hong Kong:** Flavo-G; Ginkgo Plus Vivo-Livo; Ginkgo-PS; Ginkor Fort; **Hung.:** Ginkor Fort; **Indon.:** Cereton; Ginkolan; Hemavton Brain Nutrient; Proseval; **Ital.:** Angioton; Angiovein; Forticin; Ginkoba Active; Ginkofal; Ginkoret; Memocandem; Memorandum; Neuralta Migrin; Pik Gel; Pollingel con Ginkgo Biloba; Pulsalax; Varicof; Vasobrain; Vasobrain Plus; Vasopt; Venalta; Vertiginko; **Malaysia:** Cerestart; Circarol; Ginkor Fort; Total Man; **Mex.:** Maxbiloba; **Philipp.:** Circulan; Nutrotal; **Pol.:** Bioginko; Cardiohison; Ginkgocard; Intelekt; Passibil; Venofortan; **Rus.:** Ginkor Fort (Гинкор Форте); Ginkor Gel (Гинкор Гель); **Singapore:** Ginkgo-PS; Memoloba; **Switz.:** Allium Plus; Arterosan Plus; Capsules-vital; Gincosan; Trallin; **Thai.:** Ginkor Fort; **UK:** ProBrain; **USA:** Aphroform; Cavigen; Dorofen; Gentaplex; **Venez.:** Sebiom AKN; Sengobil.

Ginkgolides

Ginkgolíidos.
Гинкголиды
CAS — 15291-75-5 (ginkgolide A); 15291-77-7 (ginkgolide B); 15291-76-6 (ginkgolide C).



Description. Ginkgolides A, B, and C (BN-52020, BN-52021, and BN-52022 respectively) are isolated from *Ginkgo biloba* (Ginkgoaceae) (see above).

Profile

Ginkgolides are terpenoid molecules isolated from *Ginkgo biloba* (above), with platelet-activating factor (PAF) antagonist properties. They have been investigated as BN-52063, a mixture of ginkgolides A (BN-52020), B (BN-52021), and C (BN-52022), for asthma and other inflammatory and allergic disorders, and also in immune disorders such as endotoxemic shock and graft rejection; ginkgolide B, which has the most potent PAF antagonist properties, has been tried alone in similar conditions. Other ginkgolides, including ginkgolide M (BN-52023) and ginkgolide J (BN-52024), have also been identified.

References.

1. Braquet P. The ginkgolides: potent platelet-activating factor antagonists isolated from *Ginkgo biloba* L: chemistry, pharmacology and clinical applications. *Drugs Of The Future* 1987; **12**: 643–99.
2. Chung KF, *et al*. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. *Lancet* 1987; **i**: 248–51.

The symbol † denotes a preparation no longer actively marketed

3. Roberts NM, *et al.* Effect of a PAF antagonist, BN52063, on PAF-induced bronchoconstriction in normal subjects. *Br J Clin Pharmacol* 1988; **26**: 65–72.

4. Kleijnen J, Knipschild P. Ginkgo biloba. *Lancet* 1992; **340**: 1136–9.

5. Houghton P. Ginkgo. *Pharm J* 1994; **253**: 122–3.

6. Brochet B, *et al.* The Ginkgolide Study Group in Multiple Sclerosis. Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. *J Neurol Neurosurg Psychiatry* 1995; **58**: 360–2.

7. MacLennan KM, *et al.* The CNS effects of Ginkgo biloba extracts and ginkgolide B. *Prog Neurobiol* 2002; **67**: 235–57.

Preparations

Proprietary Preparations (details are given in Part 3)
Turk: Bilokan; Seremaks; Tebokan.

Ginseng

Ginseng radix; Ginzenggyökér; Jintsam; Ninjin; Panax; Pannag; Renshen; Schinsent; Všehojový kořen; Ženšenü Šakıns.

Description. Ginseng is the dried root of *Panax ginseng* (*P. schinseng*) (Araliaceae). Other varieties of ginseng include *Panax quinquefolius* (American Ginseng) and *P. pseudoginseng*. The root commonly known as Siberian or Russian ginseng belongs to the same family, Araliaceae, but is an entirely different plant, *Eleutherococcus senticosus* (see Siberian Ginseng, p.2386). Brazilian ginseng is reported to be derived from another unrelated plant, *Pfaffia paniculata*.

Ginseng contains complex mixtures of saponins termed ginsenosides or panaxosides. At least 13 saponins have been isolated from extracts of *P. ginseng* roots.

Pharmacopoeias. In *Chin.*, *Eur.* (see p.vii), and *Jpn.* Also in *US* (as Asian Ginseng and American Ginseng). *US* includes additionally powdered forms of these two varieties of ginseng. *Jpn* also includes Red Ginseng, the dried root of *P. ginseng* which has been steamed.

Chin. and *Jpn* also include Rhizoma Panacis Japonica from *Panax japonicus*. *Eur.* (see p.vii) also includes Notoginseng Root from *P. notoginseng*. *Chin.* also includes Radix Notoginseng from *P. notoginseng*, and Rhizoma Panacis Majoris from *P. japonicus* var. *major* and *P. japonicus* var. *bipinnatifidus*.

Ph. Eur. 6.2 (Ginseng). The whole or cut dried root of *Panax ginseng*. It contains not less than 0.4% of combined ginsenosides, R_{g1} (C₄₂H₇₂O₁₄.2H₂O = 837.0) and R_{b1} (C₅₄H₉₂O₂₃.3H₂O = 1163.3), calculated with reference to the dried drug. Protect from light.

USP 31 (Asian Ginseng). The dried roots of *Panax ginseng* (Araliaceae). It contains not less than 0.2% of ginsenoside R_{g1} and not less than 0.1% of ginsenoside R_{b1}, both calculated on the dried basis. Store in a dry place at a temperature of 8° to 15°.

USP 31 (American Ginseng). The dried roots of *Panax quinquefolius* (Araliaceae). It contains not less than 4.0% of total ginsenosides, calculated on the dried basis. Store in airtight containers. Protect from light and heat.

Adverse Effects

◊ A 2-year study¹ of ginseng in 133 subjects who had used commercial preparations including roots, capsules, tablets, teas, extracts, cigarettes, chewing gum, and candies reported that the majority of preparations were taken orally, but a few subjects had experimented with intranasal or parenteral routes, and topical preparations had also been used. The stimulant effects of ginseng were confirmed but there was also a high incidence of adverse effects including 47 cases of morning diarrhoea, 33 of skin eruptions, 26 of sleeplessness, 25 of nervousness, 22 of hypertension, 18 of euphoria, and 14 of oedema. The 'ginseng abuse syndrome' defined as hypertension together with nervousness, sleeplessness, skin eruptions, and morning diarrhoea was experienced by 14 subjects who took ginseng orally in an average daily dose of 3 g. Abrupt withdrawal precipitated hypotension, weakness, and tremor in 1 user. About 50% of the subjects had stopped the use of ginseng within the 2 years. Oestrogenic effects have also been reported from the use of ginseng,^{2,4} and a case of Stevens-Johnson syndrome has also occurred.³

A systematic review⁶ of some of these and other studies and case reports concluded that single-ingredient preparations of ginseng were well tolerated when data from clinical studies were examined. Adverse effects were generally mild and reversible, the most common being headache, sleep disturbances, and gastrointestinal disorders. It was more difficult to determine causality from the evidence given in isolated case reports; likewise, interpretation of data involving combination products was difficult.

1. Siegel RK. Ginseng abuse syndrome: problems with the panacea. *JAMA* 1979; **241**: 1614–15.

2. Palmer BV, *et al.* Gin Seng and mastalgia. *BMJ* 1978; **1**: 1284.

3. Punnonen R, Lukola A. Oestrogen-like effect of ginseng. *BMJ* 1980; **281**: 1110.

4. Greenspan EM. Ginseng and vaginal bleeding. *JAMA* 1983; **249**: 2018.

5. Dega H, *et al.* Ginseng as a cause for Stevens-Johnson syndrome? *Lancet* 1996; **347**: 1344.

6. Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. *Drug Safety* 2002; **25**: 323–44.

Interactions

◊ For reports of interactions between *phenelzine* and ginseng, see p.419. For details of an interaction between *warfarin* and

ginseng, see p.1431. For a suggestion that ginseng may interfere with *digoxin* assays, see p.1260.

Uses and Administration

Ginseng is reported to enhance the natural resistance and recuperative power of the body and to reduce fatigue. It is available commercially as roots, powdered roots, tablets, capsules, teas, oils, or extracts.

Preparations

USNF 26: American Ginseng Capsules;
USP 31: American Ginseng Tablets; Asian Ginseng Tablets.

Proprietary Preparations (details are given in Part 3)

Arg.: Ginsana; Herbaccion Bioenergizante; Juvitan†; Transform†; Vitagen-oli†; **Austral.:** Herbal Stress Relief†; **Austria:** Ginsana; **Belg.:** Ginsana†; **Braz.:** Enerseng; Fortilique; Ginsana; Ginsex; **Canad.:** Ginsana†; **Cz.:** Ginsana; **Fr.:** Gerimax; Tonique; Ginsana†; **Ger.:** Ardey-aktiv; Coriosta Vitaltonikum N†; Ginsana; Hevert-Aktivon Mono†; IL HWA; Orgaplasma; **Ital.:** Fon Wan Ginsengery; Gi-Sen†; Ginsana; **Malaysia:** Ginsana; **Mex.:** Gincaps†; Raigin†; Rutiny; Sanjin Royal Jelly; **Pol.:** Ginsana; Ginsenol; Panaxan; **Port.:** Ginsana; **Rus.:** Gerimax Ginseng (Геримакс Женшень); Ginsana (Гинсана); **Singapore:** Ginsana; **Spain:** Bio Star; Ginsana†; **Switz.:** Ginsana; Ginsavita†; KintaVital; **Thai.:** Ginsana; Ginsroy; **UK:** Korseng; Red Kooga.

Multi-ingredient Arg.: Dynamisan; Energy Plus; Galenic Restaurador Capilar; Ginseng Bioplus Diates; Herbaccion Ginseng Y Magnesio; Holomagnesio Vital; Inteligen Ginseng†; Neuroton; Optimina Plus; Top Life Memory†; Total Magnesiano con Ginseng; Total Magnesiano con Vitaminas y Minerales; Viforol†; **Austral.:** Bioglan Ginsynergy; Clements Tonic; Extralife Extra-Brite; Ginkgo Biloba Plus†; Ginkgo Complex†; Glycyrrhiza Complex†; Infant Tonic†; Irontona; Nervatona Focus; Panax Complex†; Vig; Vitatona; **Austria:** Gerimax Plus; ProAktiv; **Braz.:** Gerin; Poliseng; **Canad.:** Damiana-Sarsaparilla Formula†; Energy Plus†; Ginkoba†; **Chile:** Gincosan; Mentania; Nectaday; **Cz.:** Gincosan; **Fr.:** Gintonal†; Nostress; Notabac; Thalgo Tonic; Tonactil†; **Ger.:** Cardibisan†; Doppelherz Ginseng Aktiv†; Ginseng-Complex "Schuh"†; Peking Ginseng Royal Jelly N†; **Hong Kong:** Cervusen; GinsengSure†; Sanjikei Panax Ginseng; **Indon.:** Armovit; Cerebrovit Active; Ginokan; Hemaviton Brain Nutrient; Hemaviton Energy Drink; Hemaviton Jreng; Instink; Maxirex; Menolia; Neo Hormoviton; Neo Hormoviton Greng; Procur Plus; Proseval; Provital Plus; Ratax; Sirec; Tripid; Tristan; **Ital.:** Alvear con Ginseng; Aperia; Bioton; Fon Wan Ginsengery; Forticin; Fosfarsile Forte; Four-Ton; Ginsana Ton; Neoplus; Ottovis; Pollingel Ginseng†; **Jpn:** Eki Cabe; **Malaysia:** 30 Plus; Adult Citrex Multivitamin + Ginseng + Omega 3; Cerestart†; Ginsomin; Imuvit; Total Man†; **Philipp.:** BSI Medicated Spray; Ginsomin; Hontamin-G Plus; Immuvit; K-A Plus; Korgivit-E; Nutroal; **Pol.:** Bioginko; Doppelherz Vital Kapseln; Ginjal; Intellektan; **Rus.:** Doppelherz Ginseng Aktiv (Доппельгерц Женшень Актив); Doppelherz Vitalotonic (Доппельгерц Виталотоник); **S.Afr.:** Activex 40 Plus; **Singapore:** Gin-Vita; Immuvital; **Spain:** Energys-or†; Esforz†; Reddeng Polivit; Ton Was Vigortonic; **Switz.:** Biovital Ginseng; Burgerstein Vitalo†; Geni; Gincosan; Imuvit; Supradin Vital 50†; Triallin; Vigoran†; **Thai.:** Imugins; Imuvit; Multimil RG; Revitan; **UK:** Red Kooga Co-Q-10 and Ginseng; Regina Royal Concorde; **Venez.:** Hivit; Pharmorat; Sengobil; Vigoran.

Glatiramer Acetate (BAN, USAN)

COP-I; Copolymer I; Glatirameerisetaatti; Glatiramer; acetato de; Glatiramer Asetat; Glatirameracetat; Glatirameri Acetas. L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate.

Глатирамер Ацетат

CAS — 28704-27-0 (glatiramer); 147245-92-9 (glatiramer acetate).

ATC — L03AX13.

ATC Vet — QL03AX13.

Adverse Effects and Precautions

Immediate post-injection reactions are common with glatiramer acetate and include chest pain, palpitations or tachycardia, dyspnoea, throat constriction, urticaria, flushing (vasodilatation), and anxiety. These reactions are generally short-lived and resolve spontaneously. They have generally occurred only some months after treatment with glatiramer was started. Other common adverse effects include asthenia, nausea, constipation, diarrhoea, rash, sweating, arthralgia, hypertonia, and dizziness. Convulsions and anaphylactoid reactions have been reported rarely. Antibodies to the drug develop with chronic therapy but are of unknown clinical significance. Pain, erythema, inflammation, mass, pruritus, and induration may occur at the injection site; localised lipotrophy and, rarely, skin necrosis has also been reported.

Glatiramer acetate should be given with caution to patients with pre-existing cardiac disorders; such patients should be followed up regularly during treatment.

◊ References.

1. Ziemssen T, *et al.* Risk-benefit assessment of glatiramer acetate in multiple sclerosis. *Drug Safety* 2001; **24**: 979–90.

Anaphylaxis. A systemic anaphylactic reaction to glatiramer acetate developed in a patient who showed a strong immunoglobulin response including specific immunoglobulin E.¹

1. Rauschka H, *et al.* Severe anaphylactic reaction to glatiramer acetate with specific IgE. *Neurology* 2005; **64**: 1481–2.

Effects on the skin. Localised lipotrophy at the injection site developed in 6 patients receiving glatiramer acetate.¹ Examination of 76 patients over a 6-month period in one centre² revealed evidence of lipotrophy in at least one injection site in 34 patients; of these, 5 cases were severe. Prevalence of lipotrophy was much higher than expected, and in some cases, it occurred only a few months after treatment started.²

Erythema nodosum confirmed by biopsy has been reported in one patient;³ spontaneous resolution occurred without stopping treatment.

1. Drago F, *et al.* Localized lipotrophy after glatiramer acetate injection in patients with relapsing-relapsing multiple sclerosis. *Arch Dermatol* 1999; **135**: 1277–8.

2. Edgar CM, *et al.* Lipotrophy in patients with multiple sclerosis on glatiramer acetate. *Can J Neurol Sci* 2004; **31**: 58–63.

3. Thouvenot E, *et al.* Erythema nodosum and glatiramer acetate treatment in relapsing-relapsing multiple sclerosis. *Multiple Sclerosis* 2007; **13**: 941–4.

Interactions

UK licensed product information reports that an increased incidence of injection-site reactions to glatiramer acetate has been seen in patients also given corticosteroids.

Pharmacokinetics

A substantial fraction of a subcutaneous dose of glatiramer is believed to be hydrolysed locally. Some of the injected dose is also presumed to enter the lymphatic system, either intact or partially hydrolysed.

Uses and Administration

Glatiramer acetate, a random polymer of L-alanine, L-glutamic acid, L-lysine, and L-tyrosine, is a polypeptide that has some structural resemblance to myelin basic protein, and is used to reduce the frequency of relapses in the management of relapsing-relapsing multiple sclerosis (p.892). It is given by subcutaneous injection in a dose of 20 mg daily. It should not be given by the intravenous or intramuscular route. An oral formulation has been investigated with disappointing results.

Multiple sclerosis. Reviews^{1,2} and a meta-analysis³ of controlled studies of glatiramer acetate in the treatment of multiple sclerosis concluded that it is of benefit, although one systematic review⁴ questions this and failed to find evidence to support its routine use. The mechanism of glatiramer acetate has also been reviewed.⁵

1. Simpson D, *et al.* Glatiramer acetate: a review of its use in relapsing-relapsing multiple sclerosis. *CNS Drugs* 2002; **16**: 825–50.

2. Ruggieri M, *et al.* Glatiramer acetate in multiple sclerosis: a review. *CNS Drug Rev* 2007; **13**: 178–91.

3. Baneschi FM, *et al.* Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. *Multiple Sclerosis* 2003; **9**: 349–55.

4. Munari L, *et al.* Therapy with glatiramer acetate for multiple sclerosis. Available in The Cochrane Database of Systematic Reviews; Issue 4. Chichester: John Wiley; 2003 (accessed 09/01/08).

5. Schrempf W, Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. *Autoimmun Rev* 2007; **6**: 469–75.

Preparations

Proprietary Preparations (details are given in Part 3)

Arg.: Copaxone; **Austral.:** Copaxone; **Austria:** Copaxone; **Belg.:** Copaxone; **Braz.:** Copaxone; **Canad.:** Copaxone; **Cz.:** Copaxone; **Denm.:** Copaxone; **Fin.:** Copaxone; **Fr.:** Copaxone; **Ger.:** Copaxone; **Gr.:** Copaxone; **Hung.:** Copaxone; **Irl.:** Copaxone; **Israel:** Copaxone; **Ital.:** Copaxone; **Mex.:** Copaxone; **Neth.:** Copaxone; **Norw.:** Copaxone; **NZ:** Copaxone; **Pol.:** Copaxone; **Port.:** Copaxone; **Rus.:** Copaxone (Копаксон); **Spain:** Copaxone; **Swed.:** Copaxone; **Switz.:** Copaxone; **Turk.:** Copaxone; **UK:** Copaxone; **USA:** Copaxone.

Glicofosfopeptical

AM-3; Fosfoglicopeptical; Glycophosphopeptical; Immunoferon.

Иммуноферон

CAS — 87139-86-4.

Profile

Glicofosfopeptical is a polysaccharide-protein complex that is reported to possess immunostimulant properties. It has been given orally in doses of 1 g every eight hours.

◊ References.

1. Alvarez-Mon M, *et al.* Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. *Chest* 2005; **127**: 1212–18.

Preparations

Proprietary Preparations (details are given in Part 3)

Mex.: Immunol; **Port.:** Imunoforon; **Spain:** Imunoforon.

Glucomanan

E425; Glucomanano; Harina de Konjac; Konjac Flour; Konjac Mannan.

Profile

Glucomanan, a powdered extract from the tubers of *Amorophallus konjac*, has been promoted as an anorectic. It has been claimed to reduce the appetite by absorbing liquid in the gastrointestinal tract. It is also used in the treatment of constipation and hyperlipidaemia. Glucomanan has been investigated as a dietary adjunct in the management of diabetes mellitus.

There is a risk of intestinal or oesophageal obstruction and faecal impaction, especially if it is swallowed dry. Therefore, it should always be taken with sufficient fluid and should not be taken